U.S. Spends Up to $34.4 Billion Annually on Uterine Fibroids

Fibroid-related obstetric complications contribute $238 million to $7.76 billion to total estimate

TUESDAY, Dec. 27 (HealthDay News) -- The total annual societal cost of uterine fibroids in the United States is estimated to range from $5.9 to $34.4 billion, based on direct and indirect costs, according to a study published online Dec. 12 in the American Journal of Obstetrics & Gynecology.

Eden R. Cardozo, M.D., from Northwestern University in Chicago, and colleagues reviewed available literature to estimate the total annual societal cost of uterine fibroids in the United States. The direct and indirect costs were estimated, including the annual number of women seeking treatment for symptomatic fibroids, medical and surgical treatment cost, obstetric complications attributable to fibroids, and work lost. The total annual costs were translated into 2010 U.S. dollars, and sensitivity was analyzed.

The investigators found that the annual estimated cost of uterine fibroids in United States ranged from $5.9 to $34.4 billion. There was an estimated $4.1 to $9.4 billion spent annually for direct costs, including medications, outpatient visits, hospital admissions, and surgery. Annual estimated cost of lost work ranged from $1.55 to $17.2 billion. The annual cost of obstetric outcomes attributed to fibroids ranged from $238 million to $7.76 billion.

"These results show that uterine fibroids may result in up to 34.4 billion dollars in total annual societal cost, and emphasize the importance of developing new effective treatments for fibroids," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing